I assume it's EPI you are talking about regarding approval. That's a Teva product and they have been at it for years so hopefully Teva working with FDA(they must have people inside the FDA HQ all the time consider all the products they have pending approval at any given point in time) will get it of the ground soon.
Very soon would be good :o)
Cache and batter,
It was not really a question I should have ended the headline "Or What?"
Batter if I controlled it, it would be 7 :o) based on the fact that my cousin in FDA had told me that EPI would get AB approval.
Just look at the last five trading days closing price and trading range...........................
You posted"Why not use Rasuvo if it cheaper ?" so I assumed you knew something about Rasuvos injector price versus whatever? Rasuvo is cheaper then what? Also the injector price will be almost totally irrelevant in a Humira/MTX combo device. It's like worrying over the cost of the cigarette lighter that you put in a Ferrari.
How do you know the price of the injectors? please share this info with us?
Price of Otrexup empty injector?
Price of Rasuvo Empty injector?
Why did you delete you post about ATRS at 1.35 because of the Pfizer gel not meeting the endpoint.
I understand that the whole thing turning into a none event must have been disappointing and that it just tuned into another stupid prediction of yours. But you should have the guts to leave it standing.
It has a reference to this,
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).
I also forgot the patents for multi dose and variable does injectors, they will not have developed those just for fun.
I'm talking about the second one in July TDP was not posting then. I think I saw something from the FDA and it seemed to apply to all. Some new warning or something like that.
Teva has to get EPI approved (IMPORTANT like nobody's business) after that we just ship the injectors they need and collect Royalty even you and I can do that.
OTREXUP will be profitable next year and the larger the user base is the faster the growth due to recurring use. We sit back and watch the ATRS sales people scurry around.
Ferrings New Injectors and dosage approved, we just ship the injectors they need and collect Royalty even you and I can do that.
SUMA should be OK the last CRL was for all sumatriptan products if I understood it right(new labeling thing).
Teva will get their bits done, the are not the largest generic drug company in the world for no reason (we probably have a more urgent timeline for the products than Teva has).
QST is looking good last estimates I saw from analysts(not this board) was 300MM a year.
BUT FDA HAVE TO APPROVE EPI FIRST OF ALL.
If Teva EPI gets A/B approval ATRS will earn between 40 and 80 MM a year on EPI alone. You work it out, use a P/E of your choice, add to that, OTREXUP will pay a profit next year, Sumatripan will ship in decent quantities and Ferring will do a decent job. Good results from QST and a possible partner announcement and disclosure of the new alliance Partnership.
A/B rated EPI is crucial.